Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

• 收藏
• 分享

专利权人:

Rhizen Pharmaecuticals SA;TG Therapeutics, Inc.;Laboratoire Francais du Fractionnement et des Biotechnologies

发明人:

WEISS, Michael,MISKIN, Hari,SPORTELLI, Peter,VAKKALANKA, Swaroop K.V.S.

申请号：

AU2018203579

公开号：

AU2018203579A1

申请日:

2018.05.22

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

#$%^&*AU2018203579A120180614.pdf#####C: Interwovn NRPortbl DCC AAR 17028598_l.docx-22 05/2018 ABSTRACT Highly effective combinations of a compound of formula A (a PI3KS selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of P13K6 and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amelioration of haematological malignancies such as leukemia and lymphoma.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/